Leukemia Home > Campath Use in Multiple Sclerosis

The U.S. Food and Drug Administration (FDA) has licensed Campath® (alemtuzumab) for the treatment of a kind of leukemia called B-cell chronic lymphocytic leukemia (B-CLL). This medication is a monoclonal antibody and works by binding to an antigen on white blood cells, which causes the cancer cells to die.
Although this drug is primarily given for B-CLL, healthcare providers may recommend the use of Campath in multiple sclerosis treatment. This is called an "off-label" use and refers to the practice of prescribing a drug for a condition it is not approved to treat. This is a common practice and is not unlawful.
(Click Campath Uses for more information on this topic, including details on whether children and older adults can use it.)
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):



Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.